132 related articles for article (PubMed ID: 35576171)
1. PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?
Blass E; Ott PA
Clin Cancer Res; 2022 Jul; 28(14):2980-2982. PubMed ID: 35576171
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naïve and Experienced Patients with Metastatic Melanoma.
Levi ST; Copeland AR; Nah S; Crystal JS; Ivey GD; Lalani A; Jafferji M; White BS; Parikh NB; Leko V; Krishna S; Lowery F; Prickett TD; Gartner JJ; Jia L; Li YF; Sachs A; Sindiri S; Robinson W; Gasmi B; Yang JC; Goff SL; Rosenberg SA; Robbins PF
Clin Cancer Res; 2022 Jul; 28(14):3042-3052. PubMed ID: 35247926
[TBL] [Abstract][Full Text] [Related]
3. Neoantigen-specific CD4
Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH; Heemskerk B; van Rooij N; Gomez-Eerland R; Michels S; van Zon M; de Boer R; Bakker NAM; Jorritsma-Smit A; van Buuren MM; Kvistborg P; Spits H; Schotte R; Mallo H; Karger M; van der Hage JA; Wouters MWJM; Pronk LM; Geukes Foppen MH; Blank CU; Beijnen JH; Nuijen B; Schumacher TN; Haanen JBAG
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753545
[TBL] [Abstract][Full Text] [Related]
5. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
6. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
7. TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.
Sznol M
Clin Cancer Res; 2021 Oct; 27(19):5156-5157. PubMed ID: 34413160
[TBL] [Abstract][Full Text] [Related]
8. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
[TBL] [Abstract][Full Text] [Related]
9. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS; Mullinax JE; Cox CA; Hall AM; Beatty MS; Blauvelt J; Innamarato P; Nagle L; Branthoover H; Wiener D; Schachner B; Martinez AJ; Richards AD; Rich CJ; Colón Colón M; Schell MJ; Teer JK; Khushalani NI; Weber JS; Mulé JJ; Sondak VK; Pilon-Thomas S; Sarnaik AA
Clin Cancer Res; 2022 Dec; 28(24):5317-5329. PubMed ID: 36215121
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
Joseph RW; Peddareddigari VR; Liu P; Miller PW; Overwijk WW; Bekele NB; Ross MI; Lee JE; Gershenwald JE; Lucci A; Prieto VG; McMannis JD; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Hwu P; Radvanyi LG
Clin Cancer Res; 2011 Jul; 17(14):4882-91. PubMed ID: 21632855
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
12. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
14. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
Kristensen NP; Heeke C; Tvingsholm SA; Borch A; Draghi A; Crowther MD; Carri I; Munk KK; Holm JS; Bjerregaard AM; Bentzen AK; Marquard AM; Szallasi Z; McGranahan N; Andersen R; Nielsen M; Jönsson GB; Donia M; Svane IM; Hadrup SR
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34813506
[TBL] [Abstract][Full Text] [Related]
16. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
17. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
18. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
19. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
[TBL] [Abstract][Full Text] [Related]
20. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]